273 related articles for article (PubMed ID: 19398857)
1. Brain tumor stem cells from an adenoid glioblastoma multiforme.
Oka N; Soeda A; Noda S; Iwama T
Neurol Med Chir (Tokyo); 2009 Apr; 49(4):146-50; discussion 150-1. PubMed ID: 19398857
[TBL] [Abstract][Full Text] [Related]
2. Partial biological characterization of cancer stem-like cell line (WJ(2)) of human glioblastoma multiforme.
Wang J; Wang X; Jiang S; Lin P; Zhang J; Wu Y; Xiong Z; Ren JJ; Yang H
Cell Mol Neurobiol; 2008 Nov; 28(7):991-1003. PubMed ID: 18350379
[TBL] [Abstract][Full Text] [Related]
3. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.
Choy W; Nagasawa DT; Trang A; Thill K; Spasic M; Yang I
Neurosurg Clin N Am; 2012 Jul; 23(3):391-405. PubMed ID: 22748652
[TBL] [Abstract][Full Text] [Related]
4. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.
Venugopal C; Hallett R; Vora P; Manoranjan B; Mahendram S; Qazi MA; McFarlane N; Subapanditha M; Nolte SM; Singh M; Bakhshinyan D; Garg N; Vijayakumar T; Lach B; Provias JP; Reddy K; Murty NK; Doble BW; Bhatia M; Hassell JA; Singh SK
Clin Cancer Res; 2015 Dec; 21(23):5324-37. PubMed ID: 26152745
[TBL] [Abstract][Full Text] [Related]
5. Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors.
Liu Q; Nguyen DH; Dong Q; Shitaku P; Chung K; Liu OY; Tso JL; Liu JY; Konkankit V; Cloughesy TF; Mischel PS; Lane TF; Liau LM; Nelson SF; Tso CL
J Neurooncol; 2009 Aug; 94(1):1-19. PubMed ID: 19468690
[TBL] [Abstract][Full Text] [Related]
6. Glioblastoma cancer stem cells--from concept to clinical application.
Stopschinski BE; Beier CP; Beier D
Cancer Lett; 2013 Sep; 338(1):32-40. PubMed ID: 22668828
[TBL] [Abstract][Full Text] [Related]
7. Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens.
Kelly JJ; Stechishin O; Chojnacki A; Lun X; Sun B; Senger DL; Forsyth P; Auer RN; Dunn JF; Cairncross JG; Parney IF; Weiss S
Stem Cells; 2009 Aug; 27(8):1722-33. PubMed ID: 19544433
[TBL] [Abstract][Full Text] [Related]
8. Isolation and partial characterization of a new human glioblastoma cell line.
Brehar FM; Bleotu C; Stefan LM; Buzgariu W; Chivu M; Utoiu E; Matei L; Ciurea AV; Tascu A
Chirurgia (Bucur); 2009; 104(4):453-61. PubMed ID: 19886054
[TBL] [Abstract][Full Text] [Related]
9. Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells.
Lathia JD; Gallagher J; Myers JT; Li M; Vasanji A; McLendon RE; Hjelmeland AB; Huang AY; Rich JN
PLoS One; 2011; 6(9):e24807. PubMed ID: 21961046
[TBL] [Abstract][Full Text] [Related]
10. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression.
Gambelli F; Sasdelli F; Manini I; Gambarana C; Oliveri G; Miracco C; Sorrentino V
Cell Biol Int; 2012 Jan; 36(1):29-38. PubMed ID: 21916848
[TBL] [Abstract][Full Text] [Related]
11. CD133/CD15 defines distinct cell subpopulations with differential in vitro clonogenic activity and stem cell-related gene expression profile in in vitro propagated glioblastoma multiforme-derived cell line with a PNET-like component.
Kahlert UD; Bender NO; Maciaczyk D; Bogiel T; Bar EE; Eberhart CG; Nikkhah G; Maciaczyk J
Folia Neuropathol; 2012; 50(4):357-68. PubMed ID: 23319191
[TBL] [Abstract][Full Text] [Related]
12. Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57.
Zhu X; Prasad S; Gaedicke S; Hettich M; Firat E; Niedermann G
Oncotarget; 2015 Jan; 6(1):171-84. PubMed ID: 25426558
[TBL] [Abstract][Full Text] [Related]
13. Type 1 collagen as a potential niche component for CD133-positive glioblastoma cells.
Motegi H; Kamoshima Y; Terasaka S; Kobayashi H; Houkin K
Neuropathology; 2014 Aug; 34(4):378-85. PubMed ID: 24673436
[TBL] [Abstract][Full Text] [Related]
14. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts.
Fan X; Khaki L; Zhu TS; Soules ME; Talsma CE; Gul N; Koh C; Zhang J; Li YM; Maciaczyk J; Nikkhah G; Dimeco F; Piccirillo S; Vescovi AL; Eberhart CG
Stem Cells; 2010 Jan; 28(1):5-16. PubMed ID: 19904829
[TBL] [Abstract][Full Text] [Related]
15. [Preliminary interpretation on the relationship between the phenotype of CD133+ cells and niche in transplanted human glioma in mice].
Song WC; Fei XF; Dong J
Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):564-9. PubMed ID: 21122405
[TBL] [Abstract][Full Text] [Related]
16. The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells.
Jamal M; Rath BH; Tsang PS; Camphausen K; Tofilon PJ
Neoplasia; 2012 Feb; 14(2):150-8. PubMed ID: 22431923
[TBL] [Abstract][Full Text] [Related]
17. Presence of pluripotent CD133+ cells correlates with malignancy of gliomas.
Thon N; Damianoff K; Hegermann J; Grau S; Krebs B; Schnell O; Tonn JC; Goldbrunner R
Mol Cell Neurosci; 2010 Jan; 43(1):51-9. PubMed ID: 18761091
[TBL] [Abstract][Full Text] [Related]
18. How powerful is CD133 as a cancer stem cell marker in brain tumors?
Cheng JX; Liu BL; Zhang X
Cancer Treat Rev; 2009 Aug; 35(5):403-8. PubMed ID: 19369008
[TBL] [Abstract][Full Text] [Related]
19. CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays.
He J; Liu Y; Zhu T; Zhu J; Dimeco F; Vescovi AL; Heth JA; Muraszko KM; Fan X; Lubman DM
Mol Cell Proteomics; 2012 Jun; 11(6):M111.010744. PubMed ID: 22203689
[TBL] [Abstract][Full Text] [Related]
20. Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling.
Annabi B; Lachambre MP; Plouffe K; Sartelet H; Béliveau R
Mol Carcinog; 2009 Oct; 48(10):910-9. PubMed ID: 19326372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
